Toxicity and efficacy of biosimilar bevacizumab in the second-line therapy for metastatic colon cancer in routine clinical practice: results of an independent observational study
M. Yu. Fedyanin, F. V. Moiseenko, M. A. Lyadova, V. N. Vorobyeva, V. V. Petkau, A. V. Fateeva, E. S. Kuzmina, O. Yu. Novikova, V. A. Chubenko, N. Kh. Abduloeva, A. A. Kudryavtsev, E. O. Ignatova, R. R. Shakirov, O. A. Pardabekova, L. V. Kindyalova, S. P. Pelikh, O. A. Gladkov, S. A. Tjulandin, A. A. Tryakin
Published in Тазовая хирургия и онкология (02.06.2021)
Published in Тазовая хирургия и онкология (02.06.2021)
Get full text
Journal Article